ZURICH (Reuters) – Roche aims to greater than double manufacture of its new coronavirus antibody test to “considerably greater than” 100 million tests per month through the finish of the season, the business’s diagnostics unit mind stated on Sunday.
The Swiss company won U.S. emergency use approval for that test that depends on taking intravenous bloodstream draws. Roche stated its test includes a specificity rate in excess of 99.8% and sensitivity rate of 100%, figures indicating very couple of false-positive tests with no false negatives.
“For bloodstream from the finger prick, you’ll never be able to offer the same degree of specificity that you’ll achieve…whenever you take bloodstream in the vein,” Roche diagnostics mind Thomas Schinecker told Reuters on Sunday. “You need very, high specificity. Even .1 or .2 percent is important.”